Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Intrinsic Value
Eckert & Ziegler Strahlen- und Medizintechnik AG engages in the provision of isotope technology for medical, scientific, and industrial use. [ Read More ]
The intrinsic value of one
EUZ
stock under the Base Case scenario is
48.24
EUR.
Compared to the current market price of 46.36 EUR,
Eckert & Ziegler Strahlen und Medizintechnik AG
is
Undervalued by 4%.
Eckert & Ziegler Strahlen und Medizintechnik AG's market capitalization is 965.5m EUR.
EUZ stock price is 46.36 EUR.
EUZ stock price (46.36 EUR) is 4% less than its Intrinsic Value (48.24 EUR).
EUZ stock price (46.36 EUR) is 14% less than its Relative Value (54.12 EUR). Open Relative Valuation
EUZ has upside potential of 35% compared to the average analyst price target.
Open Wall St Estimates
EUZ's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 9%.
EUZ's ROE (Return on Equity) for the past 12 months is positive and is equal to 12%.
EUZ has positive three-year average ROIC (Return on Invested Capital): 11%. The company is efficient at using invested capital to generate operating income.
EUZ's Revenue has grown by 11% over the past 12 months.
EUZ has positive Net Income for the last twelve months.
EUZ's Revenue is forecast to grow at a rate of 9% per year over the next 3 years.
EUZ's ROIC (Return on Invested Capital) has decreased in the last 3 years from 16% to 9%.
EUZ's ROE (Return on Equity) has decreased in the last 3 years from 19% to 12%.
EUZ's Revenue has been growing by 12% per year for the last 3 years.
EUZ has positive Operating Income for the last twelve months.
EUZ has positive Free Cash Flow for the last twelve months.
EUZ has positive three-year average ROE (Return on Equity): 16%. The company is efficient at transforming stockholders' equity into net income.
EUZ has negative Net Debt. This means that the company has more cash and short-term investments (68m EUR) than debt (47m EUR).
EUZ's long-term assets (439m EUR) exceed its long-term liabilties (217m EUR).
EUZ has positive Gross Profit for the last twelve months.
EUZ's short-term assets (234m EUR) exceed its short-term liabilties (84m EUR).
EUZ's D/E (Debt to Equity) is very low and is equal to 0.21.
EUZ's Altman Z-Score is very high and is equal to 3.94.
EUZ earns more than enough operating income (44m EUR) to safely cover interest payments on its debt (1m EUR).
Valuation Backtest
Eckert & Ziegler Strahlen und Medizintechnik AG
Run backtest to discover the historical profit from buying and selling
EUZ
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Eckert & Ziegler Strahlen und Medizintechnik AG
Balance Sheet Decomposition
Eckert & Ziegler Strahlen und Medizintechnik AG
| Current Assets | 233.7m |
| Cash & Short-Term Investments | 68m |
| Receivables | 54.4m |
| Other Current Assets | 111.2m |
| Non-Current Assets | 205.7m |
| Long-Term Investments | 32.1m |
| PP&E | 111.8m |
| Intangibles | 48.8m |
| Other Non-Current Assets | 13m |
| Current Liabilities | 83.7m |
| Accounts Payable | 5.9m |
| Other Current Liabilities | 77.8m |
| Non-Current Liabilities | 133.5m |
| Long-Term Debt | 47.4m |
| Other Non-Current Liabilities | 86.1m |
Earnings Waterfall
Eckert & Ziegler Strahlen und Medizintechnik AG
|
Revenue
|
246.1m
EUR
|
|
Cost of Revenue
|
-129.7m
EUR
|
|
Gross Profit
|
116.3m
EUR
|
|
Operating Expenses
|
-72.1m
EUR
|
|
Operating Income
|
44.2m
EUR
|
|
Other Expenses
|
-17.9m
EUR
|
|
Net Income
|
26.3m
EUR
|
Free Cash Flow Analysis
Eckert & Ziegler Strahlen und Medizintechnik AG
EUZ Profitability Score
Profitability Due Diligence
Eckert & Ziegler Strahlen und Medizintechnik AG's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Eckert & Ziegler Strahlen und Medizintechnik AG's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
EUZ Solvency Score
Solvency Due Diligence
Eckert & Ziegler Strahlen und Medizintechnik AG's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Eckert & Ziegler Strahlen und Medizintechnik AG's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EUZ Price Targets Summary
Eckert & Ziegler Strahlen und Medizintechnik AG
According to Wall Street analysts, the average 1-year price target for
EUZ
is 62.37 EUR
with a low forecast of 60.6 EUR and a high forecast of 65.42 EUR.
Shareholder Return
EUZ Price
Eckert & Ziegler Strahlen und Medizintechnik AG
| Average Annual Return | 37.14% |
| Standard Deviation of Annual Returns | 77.8% |
| Max Drawdown | -79% |
| Market Capitalization | 965.5m EUR |
| Shares Outstanding | 20 812 394 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Eckert & Ziegler Strahlen und Medizintechnik AG
Country
Industry
Market Cap
Dividend Yield
Description
Eckert & Ziegler Strahlen- und Medizintechnik AG engages in the provision of isotope technology for medical, scientific, and industrial use. The company is headquartered in Berlin, Berlin and currently employs 866 full-time employees. The company went IPO on 2008-02-25. The firm operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
Contact
IPO
Employees
Officers
The intrinsic value of one
EUZ
stock under the Base Case scenario is
48.24
EUR.
Compared to the current market price of 46.36 EUR,
Eckert & Ziegler Strahlen und Medizintechnik AG
is
Undervalued by 4%.
You don't have any saved screeners yet
